MENU
+Compare
THNR
ETF ticker: NYSE ARCA
AS OF
Jul 21, 10:57 AM (EDT)
Price
$22.69
Change
-$0.06 (-0.26%)

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
THNR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for THNR with price predictions
Jul 18, 2025

Momentum Indicator for THNR turns negative, indicating new downward trend

THNR saw its Momentum Indicator move below the 0 level on July 17, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator turned negative. In of the 13 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for THNR moved out of overbought territory on June 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 12 cases where THNR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for THNR turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where THNR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

THNR broke above its upper Bollinger Band on July 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in of 60 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 32 cases where THNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF ETF is 146.05B. The market cap for tickers in the group ranges from 330.92M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ALT at 330.92M.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was 11%. For the same ETF, the average monthly price growth was 45%, and the average quarterly price growth was 60%. TERN experienced the highest price growth at 15%, while ROG experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was -4%. For the same stocks of the ETF, the average monthly volume growth was -38% and the average quarterly volume growth was -27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 84
Price Growth Rating: 60
SMR Rating: 58
Profit Risk Rating: 75
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
THNR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details